A DNA-based vaccine approach demonstrated that CD248 can be effectively targeted immunologically; anti-tumor responses were generated in several mouse models; and CD8+/CD4+ T cell responses were elicited against peptides derived from CD248 protein. Here, CD4 is linked to neoplasm.